The search for novel antipsychotics: Pharmacological and molecular targets

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 6, 2004, Pages 631-641

  Sanger, David J ^a  

^a SANOFI   (France)

Author keywords

Acetylcholine; Dopamine; Glutamate; Neurokinins (NKs); Schizophrenia; Susceptibility genes

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 8 NITRO 1H 3 BENZAZEPIN 7 OL; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; ECOPIPAM; EGLUMETAD; EPLIVANSERIN; HALOPERIDOL; L 745 870; NEUROLEPTIC AGENT; NEUROTENSIN RECEPTOR ANTAGONIST; OLANZAPINE; OSANETANT; PHENCYCLIDINE; PRECLAMOL; RISPERIDONE; RITANSERIN; SEROTONIN 1A AGONIST; SONEPIPRAZOLE; TALNETANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE; ZIPRASIDONE;

AGITATION; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CORPUS STRIATUM; DELUSION; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TOLERABILITY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GENETIC SUSCEPTIBILITY; HUMAN; LIMBIC SYSTEM; MOLECULAR BIOLOGY; NEUROBIOLOGY; NONHUMAN; PROLACTIN BLOOD LEVEL; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; ANIMALS; ANTIPSYCHOTIC AGENTS; CHILD; CORPUS STRIATUM; DISEASE PROGRESSION; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID AGONISTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIMBIC SYSTEM; MALE; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, TACHYKININ; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 11144340872     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.6.631     Document Type: Review

References (66)

1. ROUILLON F, TOUMI M, DANSETTE GY, BENYAYA J, AUQUIER P: Some aspects of the cost of schizophrenia in France. Pharmacoeconomics (1997) 11(6):578-594.
2. MCGRATH JJ, FERON FP, BURNE TH, MACKAY-SIM A, EYLES DW: The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Ann. Med. (2003) 35(2):86-93.
3. LIDDLE PF: The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br. J. Psychiatry (1987) 151:145-151.
4. WEINBERGER D: Dopamine, the prefrontal cortex, and a genetic mechanism of schizophrebnia. In: Dopamine in the Pathoplysiology and Treatment of Schizophrenia. Kapur S, Lecrubier Y (eds), Martin Dunitz, London (2003):129-154.
5. LEUCHT S, PITSCHEL-WALZ G, ENGEL RR, KISSLING W: Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry (2002) 159(2):180-190.
6. LEUCHT S, WAHLBECK K, HAMANN J, KISSLING W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet (2003) 361 9369):1581-1589.
7. DAVIS JM, CHEN N, GLICK ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry (2003) 60(6):553-564.
8. CARLSSON A: Historical aspects and future directions. In: Dopamine in the Pathopysiology and Treatment of Schizophrenia. Kapur S, Lecrubier Y (eds), Martin Dunitz, London (2003):1-13.
9. DELAY J, DENIKER P, HARL J-M: Traitements de etats d'excitation et d'ragitation par une methode medicamenteuse derivee de l'hibernotherapic. Ann. Med. Pychol. (1952) 110:267-273.
10. ELLENBROEK BA: Animal models in the genomic era: possibilities and limitations with special emphasis on schizophrenia. Behav. Pharmacol. (2003) 14(5-6):409-417.
11. WILLNER P: The dopamine hypothesis of schizophrenia: current status, future prospects. Int. Clin. Pychopharmacol. (1997) 12 6):297-308.
12. KINON BJ, LIEBERMAN JA: Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Pychopharmacology (1996) 124(1-2):2-34.
13. REMINGTON G, KAPUR S: Atypical antipsychotics: are some more atypical than others? Pychopharmacology (2000) 148(1):3-15.
14. BRUNELLO N, MASOTTO C, STEARDO L, MARKSTEIN R, RACAGNI G: New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology (1995) 13 3):177-213.
15. KAPUR S, REMINGTON G: Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry (2001) 50(11):873-883.
16. PERRAULT G, DEPOORTERE R, MOREL E, SANGER DJ, SCATTON B: Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. (1997) 280(1):73-82.
17. SCHOEMAKER H, CLAUSTRE Y, FAGE D et al.: Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. (1997) 280(1):83-97.
18. KARLE J, CLEMMESEN L, HANSEN L et al.: NNC01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (1995) 121(3):328-329.
19. KARISSON P, SMITH L, FARDE L, HARNRYD C, SEDVALL G, WIESEL FA: Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (1995) 121(3):309-316.
20. GOLDMAN-RAKIC PS, CASTNER SA, SVENSSON TH, SIEVER LJ, WILLIAMS GV: Targeting the dopamine D(1) receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (2004) 174(1):3-16.
21. ABI-DARGHAM A: Evidence from brain imaging studies for dopaminergic alterations in schizophrenia. In: Dopamine in the Pathophysiology and Treatment of Schizophrenia. Kapur S, Lecrubier Y (eds), Martin Dunitz, London (2003):15-47.
22. KERWIN R: From pharmacological profiles to dinical outcomes. Int. Clin. Psychopharmacol. (2000) 15(Suppl. 4):S1-S4.
23. JOYCE JN: Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. (2001) 90(2-3):231-259.
24. SCHWARTZ JC, GRIFFON N, DIAZ J et al.: The D3 receptor and its relevance in psychiatry. Int. Clin. Psychopharmacol. (1995) 10(Suppl. 3):15-20.
25. JONSSON EG, FLYCKT L, BURGERT E et al.: Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr. Genet. (2003) 13(1):1-12.
26. LAHTI AC, WEILER M, CARLSSON A, TAMMINGA CA: Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J. Neural. Transm. (1998) 105(6-7):719-734.
27. CRIDER AM, SCHEIDELER MA: Recent advances in the development of dopamine D(3) receptor agonists and antagonists. Mini Rev. Med. Chem. (2001) 1(1):89-99.
28. SEEMAN P, GUAN HC, VAN TOL HH: Dopamine D4 receptors elevated in schizophrenia. Nature (1993) 365(6445):441-445.
29. SANYAL S, VAN TOL HH: Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. J. Psychiatr. Res. (1997) 31(2):219-232.
30. CORRIGAN MH, GALLEN CC, BONURA ML, MERCHANT KM: Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Sonepiprazole Study Group. Biol. Psychiatry (2004) 55(5):445-451.
31. XIBERAS X, MARTINOT JL, MALLET L et al.: Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br. J. Psychiatry (2001) 179:503-508.
32. KAPUR S, SEEMAN P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry (2001) 158:360-369.
33. SCATTON B, CLAUSTRE Y, CUDENNEC A et al.: Amisulpride: from animal pharmacology to therapeutic action. Int Clin. Psychopharmacol. (1997) 12(Suppl. 2):S29-S36.
34. LAHTI AC, WEILER MA, COREY PK, LAHTI RA, CARLSSON A, TAMMINGA CA: Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol. Psychiatry (1998) 43(1):2-11.
35. TAMMINGA CA: Partial dopamine agonists in the treatment of psychosis. J. Neural. Transm. (2002) 109(3):411-420.
36. ARGO TR, CARNAHAN RM, PERRY PJ: Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy (2004) 24 2):212-228.
37. LIEBERMAN JA: Dopamine partial agonists: a new class of antipsychotic. CNS Drugs (2004) 8(4):251-267.
38. MARONA-LEWICKA D, NICHOLS DE: Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (2004) 172 4):415-421.
39. MORTIMER AM: Novel antipsychotics in schizophrenia. Expert Opin. Investig. Drugs (2004) 13(4):315-329.
40. SCATTON B, SANGER DJ: Pharmacological and molecular targets in the search for novel antipsychotics. Behav. Pharmacol. (2000) 11:243-256.
41. MELTZER HY, LI Z, KANEDA Y, ICHIKAWA J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27(7):1159-1172.
42. MELTZER HY, MATSUBARA S, LEE JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. (1989) 251 1):238-246.
43. KAPUR S, REMINGTON G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry (1996) 153 4):466-476.
44. MELTZER HY, ARVANITIS L, BAUER D, REIN W: A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiat. (2004) 161(6):975-984.
45. WEINER DM, BURSTEIN ES, NASH N et al.: 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. (2001) 299 (1):268-276.
46. PRINSSEN EP, COLPAERT FC, KOEK W: 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur. J. Pharmacol. (2002) 453 2-3):217-221.
47. DEPOORTERE R, BOULAY D, PERRAULT G et al.: SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology (2003) 28(11):1889-1902.
48. DEUTSCH SI, ROSSE RB, SCHWARTZ BL, MASTROPAOLO J: A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. (2001) 24(1):43-49.
49. COLLIER DA, LI T: The genetics of schizophrenia: glutamate not dopamine? Eur. J. Pharmacol. (2003) 480(1-3):177-184.
50. LARUELLE M, KEGELES LS, ABI-DARGHAM A: Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. N Y Acad. Sci. (2003) 1003:138-158.
51. HERESCO-LEVY U, JAVITT DC: Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res. (2004) 66(2-3 ):89-96.
52. MILLAN MJ: N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr. Drug Target CNS Neurol. Disord. (2002) 1 2):191-213.
53. BROWN A, CARLYLE I, CLARK J et al.: Discovery and SAR of org 24598 - a selective glycine uptake inhibitor. Bioorg. Med. Chem. Lett. (2001) 11(15):2007-2009.
54. DEPOORTERE R, DECOBERT M, CUDENNEC A et al.: SSR504734, a selective and reversible inhibitor of the glycine transporter Type 1 (GLYT1): III) Effects in tests predictive of antipsychotic activity. Society for Neuroscience Meeting (2004) Abstract 349.13.
55. GOFF DC, LEAHY L, BERMAN I et al.: A placebo-controlled pilot study of the ampakine CX516 added to dozapine in schizophrenia. J. Clin. Pychopharmacol. (2001) 21(5):484-487.
56. MARENCO S, EGAN MF, GOLDBERG TE et al.: Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr. Res. (2002) 57 2-3):221-226.
57. MOGHADDAM B: Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (2004) 174(1):39-44.
58. KRYSTAL JH, D'SOUZA DC, MATHALON D, PERRY E, BELGER A, HOFFMAN R: NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (2003) 169(3-4):215-233.
59. BEAUJOUAN JC, TORRENS Y, SAFFROY M, KEMEL ML, GLOWINSKI J: A 25 year adventure in the field of tachykinins. Peptides (2004) 25(3):339-357.
60. MIRZA NR, PETERS D, SPARKS RG: Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. (2003) 9(2):159-186.
61. BYMASTER FP, FELDER C, AHMED S, MCKINZIE D: Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Target CNS Neurol. Disord. (2002) 1(2):163-181.
62. SUR C, MALLORGA PJ, WITTMANN M et al.: N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad Sci. USA (2003) 100(23):13674-13679.
63. MARTIN LF, KEM WR, FREEDMAN R: Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (2004) 174(1):54-64.
64. KITAGAWA H, TAKENOUCHI T, AZUMA R et al.: Safety, pharmacokinetics and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology (2003) 28(3):542-551.
65. BERRY N, JOBANPUTRA V, PAL H: Molecular genetics of schizophrenia: a critical review. J. Psychiatry Neurosci. (2003) 28(6):415-429.
66. HARRISON PJ, OWEN MJ: Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet (2003) 361(9355):417-419.